Lilly Presented P-II Trial Results of Orforglipron for the Treatments of Adults with Obesity or Overweight at American Diabetes Association
Shots:
- The P-II trial results evaluate orforglipron met 1EPs & 2EPs for the efficacy estimand & showed weight reductions with 1 weight-related comorbidity
- Orforglipron (12, 24, 36, or 45mg) showed dose-dependent body weight reductions for all doses ranging from 8.6%-12.6% over 2.0% in PBO at 26wk., body weight continued to decrease at 36wk. where all doses achieved body weight reductions from 9.4%-14.7% vs 2.3%. The results were published in the NEJM
- Body weight reductions of ≥5% & ≥10% in 12/24/36/45mg was 72% & 47%/90% & 62%/92% & 75%/90% & 69% vs 24% & 9% in PBO; BMI reduction were 3.4/4.7/24/5.0/5.5kg/m2 vs 0.9kg/m2; waist circumference reduction (9.6/11.2/10.6/13.6cm vs 4cm, respectively. In an additional P-II trial data published in The Lancet, orforglipron achieved a mean reduction in A1C up to 2.1% at 26wks. for T2D
Ref: PR Newswire | Image: Eli Lilly
Related News:- Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
